Table 2 Bioactive phytochemicals studied in clinical trials of patients with depression
| Drug | NCT (Country) | Pathological state | Patients (year) (age) | Dosage |
|---|---|---|---|---|
| Curcumin | NCT04744545 (United States) | Depression | 60 (2021) (>18) | 1,500 mg/day curcumin plus black pepper to aid absorption |
| NCT01750359 (Israel) | Major depression | 40 (2011) (20–65) | 500 mg/day, 6 weeks | |
| NCT01022632 (India) | Major depressive disorder | 60 (2010) (18-65) | 500 mg twice/day, 6 weeks | |
| NCT02099890 (Canada) | Neuropathic Pain, Depression, Cognitive Impairment, Somatic Neuropathy. | 20 (2015) (>18) | InflanNox capsule (400 mg curcumin) taken 3 times daily | |
| TCTR20170803002 (Thai) (Kanchanatawan |
Major depressive episode | 65 (2017) (18-63) | 500-1,500 mg/day, curcumin capsules, 12-16 weeks | |
| ACTRN12615000791538 (Australia) (Lopresti and Drummond, 2017) | Major depressive disorder | 123 (2016) (18-65) | 250 mg b.i.d. and 500 mg b.i.d., or combined 250 mg+saffron (15 mg b.i.d.) for 12 weeks | |
| Icariin | NCT01979133 (United States) (Xiao |
Bipolar I or bipolar II disorders | 11 (2015) (18-70) | 300 mg/day, 8 weeks |
| Psilocybin | NCT03181529 (United States) (Davis |
Major depressive disorder | 27 (2017) (21-75) | 20 mg/70 kg in session 1, 30 mg/70 kg in session 2 |
| ISRCTN14426797 (United Kingdom) (Carhart-Harris |
Treatment-resistant major depression | 20 (2015) (All) | 10 and 25 mg, 7days apart | |
| Equol+Resveratrol | ISRCTN10128742 (Italy) (Davinelli |
Depressive symptoms in postmenoausal women | 60 (2011) (50-55) | 200 mg of fermented soy (containing equol 10 mg+resveratrol 25 mg ) |
| Soy isoflavone | NCT00042380 (United States) | Depression | 120 (2005) (All) | Novasoy for 8 weeks |
| Sulforaphane | IRCT20090117001556N128 (Iran) (Ghazizadeh-Hashemi |
Depression with history of cardiac interventions | 66 (2020) (40-65) | 30 mg/day |